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Abstract Due to individual variations in radiosensitivity,
biomarkers are needed to tailor radiation treatment to
cancer patients. Since single nucleotide polymorphisms
(SNPs) are frequent in human, we hypothesized that SNPs
in genes that mitigate the radiation response are associated
with radiotoxicity, in particular late complications to
radiotherapy and could be used as genetic biomarkers for
radiation sensitivity. A total of 155 patients with naso-
pharyngeal cancer were included in the study. Normal
tissue fibrosis was scored using RTOG/EORTC grading
system. Eleven candidate genes (ATM, XRCC1, XRCC3,
XRCC4, XRCC5, PRKDC, LIG4, TP53, HDM2, CDKN1A,
TGFB1) were selected for their presumed influence on
radiosensitivity. Forty-five SNPs (12 primary and 33
neighboring) were genotyped by direct sequencing of
genomic DNA. Patients with severe fibrosis (cases, G3–4,
n = 48) were compared to controls (G0–2, n = 107).
Results showed statistically significant (P \ 0.05) associ-
ation with radiation complications for six SNPs (ATM G/A
rs1801516, HDM2 promoter T/G rs2279744 and T/A
rs1196333, XRCC1 G/A rs25487, XRCC5 T/C rs1051677
and TGFB1 C/T rs1800469). We conclude that these six
SNPs are candidate genetic biomarkers for radiosensitivity
in our patients that have cumulative effects as patients with
severe fibrosis harbored significantly higher number of risk
alleles than the controls (P \ 0.001). Larger cohort, inde-
pendent replication of these findings and genome-wide
association studies are required to confirm these results in
order for SNPs to be used as biomarkers to individualize
radiotherapy on genetic basis.
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Introduction
Patients vary considerably in their normal tissue response
to radiotherapy (RT) even after identical treatment (Peters
1996; Bentzen and Hendry 1999). These variations can
result in severe complications to RT that could compromise
the quality of life of cancer survivors. In the era of per-
sonalized medicine, biomarkers to predict individual
radiosensitivity are being actively sought. This is supported
by the demonstration of possible positive therapeutic gains
from tailoring the RT dose to the radiosensitivity of each
patient (Alsbeih et al. 2003; Tucker et al. 1996; Guirado
and Ruiz de Almodovar 2003). Although many treatment-
related factors could influence the severity of reactions to
RT (Turesson 1990; Bernier et al. 1998), large parts of
inter-patient variability is inherent and assumed to emanate
from genetic variations between patients (Turesson et al.
1996; Andreassen et al. 2002). The supporting evidence for
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genetic causes of increased radiosensitivity are the muta-
tions in the ataxia telangiectasis (ATM), the NBS1 (Nij-
megen Breakage Syndrome) and the DNA ligase IV (LIG
IV) genes which are components of cell cycle control and
DNA repair (Savitsky et al. 1995; Riballo et al. 1999;
Varon et al. 1998).
However, gene mutations are rare and can only explain a
minority of exquisitely sensitive patients. Therefore,
attention was focused on the more common polymorphic
variations to explain the wide range of radiosensitivity
observed (Andreassen et al. 2002). Genetic variations are
frequent in humans, and the challenge of radiogenomic
studies is to determine which polymorphisms influence
individual radiosensitivity and the risk to develop severe
complications following radiotherapy (Parliament 2012).
Single nucleotide polymorphism (SNP) is the largest type
of inherited genetic variation, of which there are at least 4.5
million (Cargill et al. 1999). The rational is that these
polymorphic variations can influence the stability of
mRNA, rate of transcription, the protein translation and/or
the protein–protein interactions leading to sub-optimal
function and expression of different degrees of clinical
radiation sensitivity. While molecular investigations
attempt to comprehend the mechanisms of action of these
small genetic changes and how they interact with host and
environmental factors, association studies provide valuable
information in determining the degree of linkage between
SNPs and radiosensitivity. The hope is to use genetic
variations as biomarkers for predictive assays to improve
treatment strategies of cancer.
The search for predictive endpoint to tailor the radiation
treatment to each individual patient’s radiosensitivity has
gone through various phases from cells to gene-based
assays. The genetic approach has been boosted by the
sequence of the human genome and with the postulation
that all-in-the-genes, it has the prospect of using genetic
variations to predict treatment outcome. This is an attrac-
tive approach because these are fixed imprint that can
nowadays be determined using DNA extracted from any
type of patient’s cells. To identify these variations, many
investigators followed an intuitive approach of targeting
SNPs in candidate genes arbitrarily involved in radiation
response (Andreassen et al. 2003, 2005, 2006a; Alsbeih
et al. 2010). Although many studies, carried out often on
limited number of RT patients, have reported significant
associations, results were globally inconsistent between
studies (Parliament and Murray 2010). In addition, a large
prospective study has failed to replicate previously repor-
ted associations between individual SNP genotype and
radiation toxicity (Barnett et al. 2012). However, genome-
wide associations study evaluating erectile dysfunction
following radiotherapy for prostate cancer has showed
significant association not only in a gene that plays a role in
male gonad development and function, but also in genes
that relate to specific African ancestry that would not have
been identified in a cohort of European ancestry (Kerns
et al. 2010).
At the molecular level, ionizing radiation can damage
various components in the cells particularly DNA (Fig. 1).
Many types of DNA damages are induced including DNA-
proteins cross-links, base damages, single and double-
strand breaks (SSBs, DSBs). Base damages and SSBs are
more frequent and are often efficiently repaired through
SSB and base-excision repair mechanisms. DSBs are
mainly repaired by two mechanisms, non-homologous end
joining (NHEJ) and homologous recombination (HR).
Notoriously, DSBs are vital and can activate panoply of
downstream molecules leading to cell cycle arrest which
allows sufficient time for the DNA to be repaired. Tissular
cytokines can also interfere in the processes, and the failure
to properly repair damage may trigger cell death through
permanent cell cycle arrest or mitochondria-controlled
apoptosis. All these signal transduction pathways interplay
to ensure maintaining genomic integrity by mediating cell
recovery or death. These pathways encompass multitude of
genes of which we have selected 11 candidate genes for
their presumed or demonstrated influence on radiosensi-
tivity (Andreassen et al. 2003, 2005; Fernet and Hall 2004;
Chang-Claude et al. 2005; West et al. 2007; Barnett et al.
2012). These include CDKN1A (p21), TP53, ATM, HDM2,
TGFB1, XRCC1, XRCC3, XRCC4, XRCC5 (Ku80),
PRKDC, and LIG4 which are involved in various pathways
(Fig. 1). Since SNPs in these genes implicated in radiation
response are likely to affect the outcome to radiation
treatment (Parliament and Murray 2010), in this study we
have genotyped 45 (12 primary and 33 neighboring) SNPs
in 155 head and neck cancer patients treated with definitive
radiotherapy, and associated with the grade of fibrosis in
normal tissues.
Materials and methods
Patients’ population and clinical data
A total of 155 head and neck cancer patients were retro-
spectively recruited, for this study, during the follow-up of
their disease. The patients were treated by definitive RT for
nasopharyngeal carcinoma in the Radiation Oncology
Section at the King Faisal Specialist Hospital and Research
Centre. This cancer site is mainly treated with radiation,
with or without chemotherapy, but it does not involve
surgery. The treatment was fairly standardized and planned
using CT-based (computerized tomography) 3D conformal
technique. The upper neck including the primary tumor site
(nasopharynx) received the maximum dose through two
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parallel–opposed–lateral fields using 6 MV photon linear
accelerator. Total radiation dose to the upper neck was
66 Gy delivered using 2 Gy per fraction per day over
6.5 weeks. Where possible, patients (n = 47) received a
boost of two additional fractions to the nasopharynx to
bring the dose received to 70 Gy in 7 weeks. In addition,
locally advanced stages (II–IVB, n = 74) received neoad-
juvant and concurrent chemotherapy consisting of cisplat-
inum and epirubicin (Al-Amro et al. 2005). The grade
(G) of subcutaneous and deep tissue fibrosis, a late radia-
tion-induced complication, was jointly scored by two par-
ticipating physicians at the recruitment visit according to
the RTOG/EORTC grading system. For group comparison,
patients with major toxicity (Cox et al. 1995), severe
fibrosis (G3–4), were referred to as the radiosensitive group
(cases, n = 48) and were compared to patients with minor
(G0–2) fibrotic reactions (controls, n = 107). The Institu-
tional Review Board (IRB) had approved the study and all
patients had signed informed consent.
DNA extraction, amplification, sequencing
and genotyping of polymorphisms
During the regular follow-up of the patients, a 5-ml blood
sample was drawn and/or 3 mm punch skin biopsy was
taken from consenting patients. Where applicable, fibro-
blast culture was established using standard protocol
(Torres et al. 2004). DNA was extracted from blood or
cultured fibroblasts using the appropriate puregene DNA
purification kit (Gentra System, USA) according to the
manufacturer’s instruction. The selected 12 primary SNPs
along with the PCR primers are listed in Table 1. Relevant
segments of DNA were amplified by thermal cycling
(95 C for 15 min, 39 rounds of 95 C for 1 min, 56 C for
1 min and 72 C for 1 min and final extension at 72 C for
7 min) using HotStarTaq DNA polymerase (Qiagen), and
50 ng template DNA in 25 lm volume with standard
reaction conditions. The amplified fragment was directly
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Fig. 1 Schematic representation of main pathways involved in
response to radiation-induced DNA damage. Base damages (BDs),
DNA single-strand breaks (SSBs) and particularly double-strand
breaks (DSBs) are the vital lesions produced. BDs and SSBs are
efficiently repaired by base-excision (BER) and SSBR mechanisms.
DSBs are repaired by two major repair mechanisms, primarily the
non-homologous end joining (NHEJ) and secondary the homologous
recombination (HR). Radiation-induced damages particularly DSBs,
activate panoply of interacting proteins in tissues, cells and
mitochondria that lead to the expression and inhibition of hundreds
of genes. These results in cell cycle arrest to allow for accurate DNA
healing before that the cells enter DNA synthesis with damaged DNA.
The aim is to maintain genomic integrity which enables recovery or
otherwise triggers cell death. Lines represent interactions. Arrows
indicate activation and blunt ends indicate inhibition. Thickness
represents the strength of the actions. Underlined font designates
encoding genes selected for this study of genetic polymorphic
variations (see text for details)
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sequencing kit (Amersham Biosciences) according to the
manufacturer’s instruction, and were run on the MegaBase
1,000 sequencer (Applied Biosystems). Sequencing results
were aligned to the corresponding reference sequence and
the primary SNPs, along with neighboring SNPs that are in
the sequenced fragments, were genotyped using SeqManII
sequence analysis software (DNASTAR Inc.).
Data analysis
The association between SNP allelic frequencies and grade
of fibrosis were measured by the odds ratio (OR) with its
95 % confidence interval. Significance of OR was assessed
by the Chi-square (v2) test. In case the latter was not
applicable, the Fisher’s exact test was used. A P value of
0.05 or less is considered statistically significant. The
alleles showing statistically significant (P B 0.05) associ-
ation with increased clinical radiosensitivity were consid-
ered as risk allele and given a score of one. Therefore,
patients homozygous for a risk allele have a score of two,
heterozygous have a score of one while patients who do not
harbor the risk allele have a score of zero. The number of
risk alleles for each patient was calculated by summing the
scores of the different SNPs significantly associated with
radiosensitivity. Difference between groups was assessed
by the non-parametric Mann–Whitney rank sum test.
Correction for multiple comparisons was carried out using
Bonferroni method, which indicates statistical significance
when the P value is lower than the type I error (0.05)
divided by the number of comparisons. Statistical analysis
was carried out using the SigmaPlot platform (Version
12.0, SPSS Science, IL, USA) and the free online soft-
wares, VassarStats: Website for Statistical Computation,
Vassar College, Poughkeepsie, NY, USA (http://faculty.
vassar.edu/lowry/odds2x2.html) and Case Control Studies:
Tests for Association, Institute of Human Genetics,




The age of patients at RT ranged between 15 and 77 years/
old with a median of 47. There were 39 females and 116
males. All patients had completed at least 24 months of
follow-up (range 24–180 months, median 40 months).
Acute reactions such as erythema, dermatitis and mucosi-
tis, were available for 62 patients only that were retrieved
from medical charts and have not been analyzed due to
small number. Late normal tissue reactions to radiotherapy
(xerostomia, skin atrophy and subcutaneous and deep tis-
sue fibrosis) were scored by two participating physicians
during the follow-up visit of the patients. Only grade of
fibrosis is reported here because it was completed for all
patients. There were 17, 54, 36, 38, and 10 patients who
had exhibited fibrotic reactions of grade 0, 1, 2, 3 and 4,
respectively. Patients classified as having major toxicity
(G3 and G4, cases) were compared to those having minor










31 C/A Ser/Arg CGCCATGTCAGAACCGGCT TTCCATCGCTCACGGGCC rs1801270





– TTTGGGGGTCTTCTGGTAAA TCCTAACTCTGATATCCCAAG rs2279744
ATM 1853 G/A Asp/Asn ATATGTCAACGGGGCATGAA CATTAATATTGCCAGTGCAAG rs1801516
XRCC1 399 G/A Arg/Gln GCCCCTCAGATCACACCTAA GATAAGCAGGCTTCACAGAGC rs25487
XRCC3 241 C/T Thr/Met GGTTAGGCACAGGCTGCTAC CTTGCTGACCAGCATAGACAA rs861539
XRCC4 247 G/T Ala/Ser GCTTACTGATAAATCTGCTGCCTA TGTATGAATGCTTGCTCACACT rs3734091
XRCC5 (Ku80) 30 UTR A/G – CAAGGGATAATTTAGACCCCATA GGGCCAAAAGGTCTTTTCTT rs1051685
LIG4 (DNA
Ligase IV)
591 A/G Ile/Val CCCTGGACGACCTAGAACAA GGAGAGCAATCCCAGGAATA rs2232641
LIG4 (DNA
Ligase IV)
9 C/T Thr/lle TCAAATTAGGGTTGGAGCAAA TTCCATAGGCCATTCTCTCTC rs1805388
PRKDC
(DNA-PKcs)
3434 A/G Ile/Thr CCTTCCATTAGAGTGCCAT ATGCACTGCACACACTAACG rs7830743
TGFB1
(TGFb1)
10 C/T Leu/Pro AGCCTCCCCTCCACCACT TGGGTTTCCACCATTAGCAC rs1982073
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Fig. 2 Genotypes’ distribution of 20 SNPs that showed five or more individuals with minor alleles in 155 nasopharyngeal cancer patients who
developed minimal (0–2) or severe (3–4) grade of radiation-induced fibrosis
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Table 2 Allele frequencies of the assessed polymorphisms in 155 head and neck cancer patients who either developed minimal (controls: G0–2)
or severe (cases: G3–4) late reactions (fibrosis) after radiotherapy
Gene and SNP Allele 1a Allele 2b Odds ratio P value
Cases Controls Cases Controls (95 % CI)
n (%) n (%) n (%) n (%)
CDKN1A C/A rs1801270 74 (77) 157 (73) 22 (23) 57 (27) 0.82 (0.47–1.44) 0.49
TP53 G/C rs1042522 52 (54) 112 (52) 44 (46) 102 (48) 0.93 (0.57–1.51) 0.76
TP53 C/T rs1800371 96 (100) 213 (99.5) 0 (0) 1 (0.5) 0 1.00*
ATM G/A rs1801516 82 (85) 202 (94) 14 (15) 12 (6) 2.86 (1.18–6.48) <0.01
ATM A/T rs1801673 96 (100) 214 (100) 0 (0) 0 (0) – –
HDM2 G/C rs7484572 96 (100) 214 (100) 0 (0) 0 (0) – –
HDM2 T/G rs2279744 71 (74) 125 (58) 25 (26) 89 (42) 0.49 (0.29–0.84) <0.01
HDM2 T/A rs1196333 95 (99) 198 (93) 1 (1) 16 (7) 0.13 (0.02–0.99) 0.02
TGFB1 G/A rs9282871 95 (99) 213 (99.5) 1 (1) 1 (0.5) 2.24 (0.14–36.23) 1.00*
TGFB1 C/T rs1982073 40 (42) 102 (48) 56 (58) 112 (52) 1.28 (0.78–2.07) 0.32
TGFB1 G/C rs1800471 92 (96) 207 (97) 4 (4) 7 (3) 1.28 (0.37–4.50) 0.74*
TGFB1 C/T rs4987025 96 (100) 214 (100) 0 (0) 0 (0) –
TGFB1 C/T rs1800469 67 (70) 122 (57) 29 (30) 92 (43) 0.57 (0.34–0.96) 0.03
TGFB1 G/A rs11466314 96 (100) 213 (99.5) 0 (0) 1 (0.5) 0* 1.00*
TGFB1 C/T rs35318502 96 (100) 214 (100) 0 (0) 0 (0) – –
TGFB1 del rs8179182 94 (98) 214 (100) 2 (2) 0 (0) 3.28** (2.77–3.88) 0.10*
TGFB1 C/A rs35383147 96 (100) 214 (100) 0 (0) 0 (0) – –
TGFB1 ins rs34233206 96 (100) 214 (100) 0 (0) 0 (0) – –
TGFB1 C/T rs1800472 92 (96) 199 (93) 4 (4) 15 (7) 0.58 (0.19–1.79) 0.33
TGFB1 C/T rs11466334 95 (99) 213 (99.5) 1 (1) 1 (0.5) 2.24 (0.14–36.22) 1.00*
XRCC1 G/A rs2271980 96 (100) 214 (100) 0 (0) 0 (0) – –
XRCC1 G/A rs25487 83 (86) 155 (72) 13 (14) 59 (28) 0.41 (0.21–0.79) <0.01
XRCC1 C/T rs3213368 87 (91) 193 (90) 9 (9) 21 (10) 0.95 (0.42–2.16) 0.90
XRCC1 G/A rs2139720 88 (92) 190 (89) 8 (8) 24 (11) 0.72 (0.31–1.67) 0.44
XRCC1 C/T rs3213369 96 (100) 213 (99.5) 0 (0) 1 (0.5) 0 1.00*
XRCC3 G/A rs41285494 96 (100) 214 (100) 0 (0) 0 (0) – –
XRCC3 G/A rs861539 55 (57) 133 (62) 41 (43) 81 (38) 1.22 (0.75–1.99) 0.42
XRCC3 A/C rs3212112 95 (99) 213 (99.5) 1 (1) 1 (0.5) 2.24 (0.14–36.22) 1.00*
XRCC3 C/T rs3212113 96 (100) 214 (100) 0 (0) 0 (0) – –
XRCC4 A/C rs2974446 96 (100) 214 (100) 0 (0) 0 (0) – –
XRCC4 G/T rs3734091 95 (99) 213 (99.5) 1 (1) 1 (0.5) 2.24 (0.14–36.23) 1.00*
XRCC5 A/G rs41296835 96 (100) 213 (99.5) 0 (0) 1 (0.5) 0 1.00*
XRCC5 T/C rs1051677 89 (93) 178 (83) 7 (7) 36 (17) 0.39 (0.17–0.91) 0.02
XRCC5 G/T rs41437350 96 (100) 214 (100) 0 (0) 0 (0) – –
XRCC5 A/G rs1051685 85 (89) 195 (91) 11 (11) 19 (9) 1.33 (0.61–2.91) 0.48
PRKDC T/C rs7830743 93 (97) 197 (92) 3 (3) 17 (8) 0.37 (0.11–1.31) 0.11
PRKDC A/G rs8178228 96 (100) 214 (100) 0 (0) 0 (0) – –
LIG4 T/C rs1805384 90 (94) 200 (93) 6 (6) 14 (7) 0.95 (0.36–2.56) 0.92
LIG4 C/A rs1805383 96 (100) 214 (100) 0 (0) 0 (0) – –
LIG4 C/T rs4987182 93 (97) 209 (98) 3 (3) 5 (2) 1.35 (0.32–5.76) 0.71*
LIG4 C/T rs1805389 95 (99) 206 (96) 1 (1) 8 (4) 0.27 (0.03–2.20) 0.28*
LIG4 C/T rs1805388 91 (95) 195 (91) 5 (5) 19 (9) 0.56 (0.20–1.56) 0.26
LIG4 G/A rs2232636 96 (100) 214 (100) 0 (0) 0 (0) – –
LIG4 G/A rs2232641 96 (100) 214 (100) 0 (0) 0 (0) – –
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reactions (G0, G1 and G2, controls) (Cox et al. 1995).
Therefore, patients with severe subcutaneous and/or deep
tissue fibrosis (G3–4, cases, n = 48) were referred to as
radiosensitive and were compared to the remaining patients
having no, mild or moderate fibrosis (G0–3, controls,
n = 107). The distribution of controls and radiosensitive
patients according to chemotherapy and radiation boost
received were comparable. Briefly, 79 and 54 patients had
received chemotherapy and RT boost; respectively, who
were proportionally distributed between controls and cases.
Thus, the ratio of patients who received chemotherapy to
the patients who did not were comparable in the control
and the radiosensitive groups (0.50 vs. 0.52, P = 0.80).
Similarly, the average total doses received (with and
without boost) in controls (67.50 Gy, SD = 1.94) and in
the radiosensitive groups (67.17 Gy, SD = 1.84) were not
significantly different (P = 0.35).
Genotyping analysis
A total of 45 SNPs were genotyped. These were detected in
12 DNA fragments of 11 genes (1 in CDKN1A; 2 in TP53,
ATM, PRKDC, XRCC4; 3 in HDM2; 4 in XRCC3, XRCC5;
5 in XRCC1; 8 in LIG4; 12 in TGFB1). In numbers, 15
SNPs were all wild types and 10 SNPs showed 1 or 2
variant genotype. There were 20 SNPs having variant
genotypes frequency [2; the distribution of which in
relation to late radiotoxicity (grade of fibrosis) is depicted
in Fig. 2. There were wide variations in the distribution of
the different genotypes according to the grade of fibrosis.
The allelic frequencies of the 45 assessed SNPs are
given in Table 2. Comparison between cases and controls
revealed statistically significant association (P \ 0.05) for
six SNPs (ATM rs1801516, HDM2 rs2279744, HDM2
rs1196333, TGFB1 rs1800469, XRCC1 rs25487 and
XRCC5 rs1051677). Interestingly, apart from ATM where
the variant A allele was associated with increased risk, the
variant alleles of the remaining significantly associated
SNPs showed decreased risk (odds or risk ratios \1) to
develop severe fibrosis, and therefore, they exhibit
protective effect. The association observed for ATM
rs1801516, HDM2 rs2279744, XRCC1 rs25487 remains
statistically significant after taking into consideration
multiple comparisons using Bonferroni correction.
Influence of the number of risk alleles on the grade
of fibrosis
The alleles that showed statistically significant associations
with increased risk to develop severe fibrosis (the variant
allele for ATM rs1801516 and the majority or wild-type
alleles of HDM2 rs2279744, HDM2 rs1196333, TGFB1
rs1800469, XRCC1 rs25487 and XRCC5 rs1051677) have
been counted to calculate the number of risk alleles for
each patient (see ‘‘Data analysis’’). The number of risk
alleles ranged between 3 and 10 (median = 7) in controls
compared to 5–11 (median = 9) in the radiosensitive
patients. The relationship between the number of risk
alleles and clinical radiosensitivity (G0–2 compared to
G3–4) has been analyzed by box plot (Fig. 3). Although
variations were present, patients who developed severe
fibrosis (G3–4) showed a clear trend to harbor higher
number of risk alleles. The comparison between the two
groups showed a statistically significant difference in the
median number of risk alleles between cases and controls
(Mann–Whitney test, P \ 0.001).
Discussion
The aim of this study was to evaluate in our local cancer
patients whether genetic polymorphic variations in candi-
date genes involved in radiation response mediated through
cell cycle control and DNA repair mechanisms (Fig. 1) are
associated with the severity of RT-induced fibrotic reac-
tions in normal tissues. The 155 head and neck cancer
patients included in this report had nasopharyngeal carci-
noma. This cancer site is prevalent in Saudi Arabia and is
ideal for this type of study because patients follow stan-
dardized treatment with curative radiation without surgery.
Table 2 continued
Gene and SNP Allele 1a Allele 2b Odds ratio P value
Cases Controls Cases Controls (95 % CI)
n (%) n (%) n (%) n (%)
LIG4 A/G rs3093766 96 (100) 214 (100) 0 (0) 0 (0) – –
Significantly associated SNPs are highlighted in bold
* P value represents the 2-tailed Fisher’s exact test, calculated in case the Chi-square cannot be determined, ** risk ratio (RR) is calculated when
odds ratio (OR) is inaccurate
a Allele 1: majority or wild-type allele
b Allele 2: minority or variant allele
3 Biotech (2014) 4:137–148 143
123
Radiotherapy is the main treatment and it was delivered
using 6 MV photon linear accelerator. The standard
cumulative radiation dose to the upper neck, where radia-
tion effects are scored, was 66 Gy given as 2 Gy per
fraction. A boost of two fractions to the nasopharynx,
which bring the total dose to 70 Gy, was given to certain
patients taking into consideration the stage of the disease
and the judgment of the treating physician. Locally
advanced tumors are also treated with neoadjuvant and
concurrent chemotherapy consisting of cisplatinum and
epirubicin (Al-Amro et al. 2005).
Patients were enrolled in the study during the follow-up
of their disease. Only those who completed at least 2 years
of follow-up were reported here. This is in principle suf-
ficient for the appearance and the intensification of late
radiotoxicity (Barnett et al. 2012). Although various end
points of acute and late complications following radio-
therapy were scored for each patient, data on subcutaneous
and deep tissues fibrosis were completed for all 155
reported patients. Associated diseases were uncommon: 15
patients had diabetes (10 in controls and 5 in cases), 7 were
hypertensive (3 in controls and 4 in cases), 2 patients with
systemic lupus erythematous (controls) and 1 patient had
scleroderma with severe Raynaud’s phenomena (control).
Thus, the associated diseases do not account for the
observed differences in radiotoxicity in this cohort.
To maximize chances of seeing differences, patients
with severe subcutaneous or deep tissue fibrosis (G3–4,
cases, n = 48) were compared to patients with minimal to
moderate fibrosis (G0–2, controls, n = 107). This classi-
fication is slightly different from that reported in earlier
where G0–1 group was compared to G2–3 because there
was no G4 in that pilot study (Alsbeih et al. 2010).
Treatment characteristics were comparable between the
radiosensitive cases and the controls; taking into account
the total radiation dose and the chemotherapy received.
Thus, overall no differences could be attributed to associ-
ated diseases or treatment-related factors.
The 12 candidate primary polymorphisms included in
this study (Table 1) were selected based on previous
reports on the potential association between radiosensitiv-
ity and SNPs (Andreassen et al. 2002; Alsbeih et al. 2010;
Barnett et al. 2012) or radiation-induced levels of the
encoded protein (Alsbeih et al. 2009a). Since we have used
direct DNA sequencing technique, it was possible to
genotype neighboring SNPs. This allowed genotyping of
45 SNPs in the 11 candidate genes (Table 2). These genetic
variations were either synonymous, nonsynonymous,
insertion or deletion that may have impact on protein level
and contribute to variations between patients.
Among the 45 genetic variations scored, six SNPs (ATM
rs1801516, HDM2 rs2279744, HDM2 rs1196333, TGFB1
rs1800469, XRCC1 rs25487 and XRCC5 rs1051677)
showed significant association (P \ 0.05) between allelic
frequency and grade of fibrosis following RT (Table 2).
Moreover, the association found for ATM rs1801516,
HDM2 rs2279744 and XRCC1 rs25487 remained statisti-
cally significant after taking into consideration Bonfer-
roni’s multiple comparisons correction. As compared to the
controls (G0–2), the radiosensitive group (G3–4) harbored
relatively higher number of variant ATM rs1801516
A allele which appeared to be a risk factor (OR = 2.86, CI
95 % 1.18–6.48, P \ 0.01), and lower numbers of the
variants HDM2 rs2279744 G (OR = 0.49, CI 95 %
0.29–0.84, P \ 0.01), HDM2 rs1196333 A (OR = 0.13, CI
95 % 0.02–0.99, P = 0.02), TGFB1 rs1800469 T
(OR = 0.57, CI 95 % 0.34–0.96, P = 0.03), XRCC1
rs25487 A (OR = 0.41, CI 95 % 0.21–0.79, P \ 0.01), and
XRCC5 rs1051677 C (OR = 0.39, CI 95 % 0.17–0.91,
P = 0.02) alleles which appeared to have protective effect;
therefore, the wild-type alleles were the risk factors. These
are interesting results that plead in favor of the potential
use of genetic markers as predictors of normal tissue
response, particularly that the subject is a hot topic debate
(Barnett et al. 2012).
To our knowledge, this is the first study on the associ-
ation between HDM2 T309G promoter (rs2279744) and
radiosensitivity; previous studies were only concerned with
its cancer predisposing potential (Bond et al. 2005; Sun
et al. 2010; Al-Hadyan et al. 2012). The HDM2 gene
encodes a protein that is a key component of TP53 protein
signaling pathway (Fig. 1). HDM2 is transcriptionally
activated by TP53 (Barak et al. 1993). It regulates the
function of TP53 in several ways including the ubiquitin
E3 ligase for TP53 and targets its degradation by the
Fig. 3 Box plot analysis of the relationship between the number of
risk alleles and clinical radiosensitivity of the two groups of cancer
patients who either developed minimal (G0–2) or severe (G3–4)
fibrotic reaction. Bold lines indicate the median number of risk alleles.
Upper and lower boundaries of boxes indicate the 75th and 25th
percentile. Bars above and below boxes indicate the 90th and 10th
percentiles. Data points represent outliers
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proteasomal pathway (Honda et al. 1997); HDM2 is
responsible for the nuclear to cytoplasmic shuttling of
TP53, thus inhibiting its function as a transcription factor
(Roth et al. 1998). HDM2 also binds TP53 and inhibits
transactivation (Momand et al. 1992). Although mutations
in HDM2 are infrequent (Tamborini et al. 2001), HDM2
protein is overexpressed in about 5–10 % of human tumors
(Ladanyi et al. 1993). In addition, HDM2 protein interacts
with the S phase-promoting factor, E2F1, and increases its
function (Martin et al. 1995). These two proteins were also
found to interact with a number of heterogeneous nuclear
ribonucleoproteins (hnRNP), which orchestrate mRNA
processing in response to ionizing radiation (Haley et al.
2009).
The functional polymorphic variant in the HDM2 pro-
moter at position 309 (rs2279744) have been suggested to
affect the transcriptional activator SP1 binding, thereby
modulating HDM2 transcription level. The G variant has
been shown to increase the affinity for Sp1, resulting in
higher levels of HDM2 mRNA and protein and the sub-
sequent attenuation of the TP53 pathway (Bond et al.
2004). The impact of this genetic variation on HDM2
levels have a snow-balling effect on TP53 amounts in the
cell, and the G allele which leads to higher HDM2 tran-
scription was shown to attenuate the TP53 response which
could alter cellular response to radiation therapy and DNA-
damaging drugs (Nayak et al. 2007). Results presented here
showed that the same variant G allele, and also the variant
G allele in the neighboring HDM2 rs2279744 SNP, is
associated with reduced risk to develop late normal tissues
complications, a phenomenon that is dependent on the
amount of cell depletion following radiotherapy. There-
fore, in line with our results, it is conceivable that this
HDM2 G variant allele could promote cell survival fol-
lowing irradiation and thus, cells would appear more
radioresistant, despite the probable high risk of genomic
instability due to presumably attenuated TP53 (Fig. 1).
This may also have implication for the promotion of sec-
ondary cancers following radiotherapy.
This is also the first study to report association between
XRCC5 (KU80) polymorphisms and clinical radiosensi-
tivity. XRCC5 is a component of the non-homologous end
joining (NHEJ) to repair DNA double-strand breaks
(Fig. 1). Previously, SNPs in XRCC5 have been shown to
influence cancer risk and chromosomal radiosensitivity
(Willems et al. 2008; Al-Hadyan et al. 2012). Our study
showed that, although uncommon, the variant XRCC5
rs1051677 C allele was more frequent in the controls
(Fig. 2), thus it has a protective effect.
As reported previously, the variant ATM rs1801516
A allele (Asn) was significantly associated with increased
radiation sensitivity (Andreassen 2005; Alsbeih et al.
2007b). Other studies have also shown similar association
with enhanced risk of various adverse reactions after RT
for breast and prostate cancer (Angele et al. 2003; Hall
et al. 1998; Andreassen et al. 2006b). In contrast, the wild
type or majority XRCC1 rs25487 allele (Arg) was associ-
ated with increased risk to develop late reactions to
radiotherapy (reviewed in Andreassen 2005). This suggests
that the variant (or minority) allele could confer higher
radioresistance in favor of normal tissues involved in the
radiation treatment. The XRCC1 protein is required for
efficient DNA single-strand breaks repair to maintain
genomic stability (Fig. 1). Its reduction leads to increased
sensitivity to cell killing by ionizing radiation (Brem and
Hall 2005). Although the codon 399 is situated in the
BRCT I active domain of the protein, both wild type and
variant alleles were found to be in vitro equally functional
(Taylor et al. 2002). The results of present and similar
clinical studies seem to be counter intuitive to in vitro
studies; however, a study by Brem et al. (2006) suggested
that it is the haplotype in the XRCC1 gene (i.e., segregation
with other SNPs) rather than the G28152A SNP per se that
is associated with cellular or clinical radiosensitivity.
TGFB1 encodes for the versatile cytokine TGFB1 which
is assumed to be involved in the tissular modulation of
inflammation in response to tissue injuries (Fig. 1).
Therefore, SNPs that can modulate protein production can
result in excessive deposition of scar tissue and fibrosis
(Border and Noble 1994). Therefore, many SNPs have
been studied in the literature. Between 12 neighboring
TGFB1 polymorphisms, the significantly associated SNP
rs1800469 seems to be different from the rs1982073
reported previously (Alsbeih et al. 2010), but in agreement
with other studies (Andreassen et al. 2003; Azria et al.
2008; Giotopoulos et al. 2007; Quarmby et al. 2003). Thus,
the effect of haplotype needs to be clarified as co-segre-
gation of polymorphic variations in TGFB1 gene has been
suggested to play a role in radiation response. De Ruyck
et al. (2006) have reported that three different variations in
TGFB1 were associated with the risk of developing late
severe reactions after gynecologic RT, where analysis
revealed two major haplotypes but could not distinguish
radiosensitive from nonradiosensitive patients.
This study, however, did not show significant associa-
tion for SNPs in CDKN1A, TP53, LIG IV, PRKDC, XRCC3
and XRCC4. These negative results, however, do not
negate the importance of these genes to radiosensitivity as
mutations in TP53 and LIG IV are well-known example of
genetic disorder with potential impact on radiosensitivity.
In addition, an association between TP53 G72T and in vitro
cellular radiosensitivity was reported (Alsbeih et al.
2007a). This strengthens the widely held belief that the
correlation between cellular and clinical radiosensitivity is
somewhat weak and overwhelmed with multitude of tissues
and patient-related factors. In addition, in a large
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independent dataset Barnett et al. (2012) also could not
validate previously reported associations between genotype
and radiation toxicity. Furthermore, our results do not
exclude other genetic variations in these genes and larger
studies are required to unravel the influence of subtle
genetic changes on radiation response.
The risk alleles associated with increased clinical
radiosensitivity were either variant or wild type (Table 1).
This indicates that not all variant SNPs are risky. From an
evolutionary perspective, it is possible that the substitutions
observed frequently are likely to be neutral or favorable,
whereas those observed rarely are likely to be deleterious
(Zhu et al. 2004). More importantly, group comparison
between cases and controls showed statistically significant
difference in the median number of risk alleles (P \ 0.001)
with the radiosensitive group (G3–4) harboring higher
number of risk alleles (Fig. 3). This is an important dem-
onstration of the combined effect of different genetic
variations and supports the assumption that radiosensitivity
is a complex genetic trait. Therefore, harboring higher
number of risk alleles has incremental effect on compli-
cations to radiotherapy. This illustrates that radiation
response requires the concerted action of multiple genes
and, therefore, it is a complex genetically controlled trait
with the outcome being determined by multitude of addi-
tive effects. This conclusion is further substantiated by the
assumption that the combined risk alleles effect on radio-
sensitivity may also incorporate variations in mitochondrial
DNA, the energy producing cytoplasmic organelles, as a
subset of patients of this study have also showed associa-
tion with genetic variations in mtDNA (Alsbeih et al.
2009b). The genomic revolution with the advent of high-
throughput techniques can help uncovering the panoply of
these interacting factors at the DNA (genome), RNA
(transcriptome) or protein (proteome) level. Research using
genome-wide analysis tools heralds the future of individ-
ualized radiation treatment in broadly personalized medi-
cine. In addition to predictive testing, the identified genes
and their products could become targets for innovative
therapies in radiosensitive individuals.
Conclusions
Between 45 SNPs in 11 genes involved in cell cycle control
and DNA repair, 6 showed significant association with
radiation toxicity in Saudi radiotherapy patients. Although
many of these SNPs were studied before with variable
results, this is the first study to include SNPs in HDM2
gene where two SNPs in the promoter region were sig-
nificantly associated with fibrotic reaction. In addition, the
radiosensitive patients harbored significantly higher num-
ber of risk alleles than the controls (P \ 0.001). Larger
cohort, independent replication of these findings and gen-
ome wide association studies (GWAS) are required to
confirm these results and validate the use of SNPs as bio-
markers to individualize radiotherapy on genetic basis.
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